Compare VSTS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | CTMX |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 977.1M |
| IPO Year | 2023 | 2015 |
| Metric | VSTS | CTMX |
|---|---|---|
| Price | $9.48 | $4.89 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $5.88 | ★ $12.10 |
| AVG Volume (30 Days) | 979.3K | ★ 6.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,734,839,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.67 | $18.75 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.98 | $0.63 |
| 52 Week High | $9.80 | $8.21 |
| Indicator | VSTS | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 78.30 | 55.54 |
| Support Level | $7.24 | $3.94 |
| Resistance Level | $9.80 | $6.20 |
| Average True Range (ATR) | 0.32 | 0.28 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 94.57 | 84.95 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.